New research report on Food Biotechnology market, which is a detailed analysis of this business space inclusive of the trends, competitive landscape, and the market size. Encompassing one or more parameters among product analysis, application potential, and the regional growth landscape, Food Biotechnology market also includes an in-depth study of the industry's competitive scenario.

Rising concern pertaining to global food insecurity in developing countries with rising population will propel the food biotechnology market. As per FDA, area under biotech crop production increased by 4.7 million hectares in 2017 due to higher commodity prices for consumable products and increasing demand in developing economies. India, Brazil, Pakistan, Mexico, Colombia, etc. have increased the area under genetically modified crop production to meet the rising demand with growing population.

Changing dietary patterns and growing demand for processed items has urged the food & beverage manufacturers to improve the nutritional content in their products. Global processed-food industry is estimated to be valued over USD 3.2 trillion in 2018 and 80% of agricultural products in the developed countries get processed and packaged. Strong demand for high-quality functional ingredients by food processing companies will create lucrative opportunities for food biotechnology market players over the forecast period.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5455

Increasing technological advancements in food industry will drive the food biotechnology market. Shifting consumer focus towards food quality, taste, nutrition and shelf life will support demand for genetically modified plants and animals. Changing climatic conditions and farming loss are expected to support production of genetically modified crops. Growing concern pertaining to usage of pesticides and herbicides for the crop yield will support penetration of innovative technologies over the projected timeframe.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/5455

Transgenic crop is expected to observe growth over 9% in terms of revenue up to 2025. Factors such as low labor & production cost, reduced application of chemical inputs and better economic gains are among the key factors that will positively influence the segment growth. In addition, growing subcontract agreements between private firms and the farmers to boost genetically modified crops production, will foster overall food biotechnology market over the forecasted timeframe.

North America food biotechnology market is anticipated to hold over 29% share in 2018. U.S. is the largest producer of genetically modified crops for commercial purpose, thus supporting overall regional growth. More than 93% of the corn, soy and cotton cultivated in the country are genetically modified. About 70% of the processed food in the U.S. are manufactured using genetically modified ingredients. In addition, increasing demand for processed and packaged products owing to busy lifestyle will foster the regional food biotechnology market share.

Rapid expansion of beverage sector will also provide new growth opportunities in the food biotechnology market share. Fermentation is the key process used in beverage and bakery industry, thus creating new avenues for industry participants. Emerging middle-class consumers in developing economies with rapid urbanization is anticipated to propel implementation of biotechnology solutions in beverage sector. Increasing demand for high-quality & premium beverages accompanied rising disposable income will support manufacturers investment in new product development.

Global food biotechnology market is competitive in nature due to the presence of large multinational and regional players. Key industry participants include BASF SE, Bayer Crop Science AG, AquaBounty Technologies, Dow AgroSciences LLC, ABS Global, Arcadia Biosciences, BDF Ingredients Zuchem, Camson Bio Technologies Ltd and Monsanto. New product development, mergers and acquisition, geographical expansion are few strategies adopted by the participants.

Major Highlights from Table of contents are listed below for quick lookup into Food Biotechnology Market report

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Food Biotechnology Industry Insights

Chapter 4. Company Profiles

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/5455

Read this article:
2025 Food Biotechnology Market |Top Companies, Trends and Future Prospects Details for Business Development - The Research Process

A rating of 78 puts Axsome Therapeutics Inc (AXSM) near the top of the Biotechnology industry according to InvestorsObserver. Axsome Therapeutics Inc's score of 78 means it scores higher than 78% of stocks in the industry. Axsome Therapeutics Inc also received an overall rating of 65, putting it above 65% of all stocks. Biotechnology is ranked 23 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 65 means the stock is more attractive than 65 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Axsome Therapeutics Inc (AXSM) stock is trading at $77.45 as of 2:13 PM on Monday, Sep 21, a loss of -$4.20, or -5.14% from the previous closing price of $81.65. The stock has traded between $77.23 and $83.27 so far today. Volume today is 375,402 compared to average volume of 430,624.

Click Here to get the full Stock Score Report on Axsome Therapeutics Inc (AXSM) Stock.

See the article here:
Is Axsome Therapeutics Inc (AXSM) the Top Pick in the Biotechnology Industry? - InvestorsObserver

One of the biggest winners among coronavirus stocks in 2020 has been Vir Biotechnology(NASDAQ:VIR). The company's shares have more than doubled in the span of one year, turning a $10,000 investment from last September into about $22,700 today. That substantially outperformed the S&P 500, which gained 15% over the same period.

But sometimes, the higher you climb, the harder you fall. Recent controversy surrounding the company's progress with its COVID-19 programs caused the stock to fall more than 40% from its peak in late August. Should investors expect this company and its stock to rebound? Let's take a look at whether buying Vir on the dip is a golden opportunity or whether the company's drug pipeline spells trouble for its future.

Image Source: Getty Images.

Vir has two antibody treatments and a small interfering RNA (siRNA) treatment against COVID-19 in its pipeline. siRNA therapeutic candidates are based on tiny double-stranded RNA sequences coded to destroy genetic material responsible for a virus' protein synthesis, rendering it unable to replicate. The RNA treatment is undergoing preclinical studies, the results from which are expected by the end of the year. Meanwhile, one of the company's antibodies, VIR-7832, will enter phase 2 clinical trials in the fourth quarter, while the other, VIR-7831, is in phase 2/3 clinical trials. The latter candidate could made available first under an early access program like an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in the early months of 2021, if trial results are positive.

Vir has partnered with GlaxoSmithKline(NYSE:GSK) to develop its COVID-19 programs. The company is responsible for research and development (R&D) costs while GlaxoSmithKline is handling commercialization costs. Under the agreement, 72.5% of costs and profits go to Vir while the remaining 27.5% are GlaxoSmithKline's.

Without a doubt, Vir's pipeline has potential. However, there are already coronavirus treatments on the market, including Gilead Sciences'(NASDAQ:GILD) antiviral, remdesivir, and the generic steroid, dexamethasone. What's more, large-cap biotechs such as Moderna(NASDAQ:MRNA) andPfizer(NYSE:PFE) are already far along in their efforts to develop coronavirus vaccines. In fact, a vaccine could be available as soon as October. While there are no guarantees that any one of the vaccine candidates in particular will prove effective against COVID-19, it is likely that by 2022, the need for coronavirus treatments will have significantly diminished as people around the world are (hopefully) inoculated.

The company's hepatitis B pipeline is facing similar problems. Even though its treatment candidates for the disease are well into phase 2 trials, the question of their commercial feasibility is a key concern. There are already a number of effective hepatitis B vaccines available worldwide, meaning that the need for a treatment is limited to those who don't get immunized (or those whose immunizations are ineffective) and subsequently contract the virus. While 257 million people are currently living with hepatitis B, many are in developing nations and may not have the purchasing power to afford a pricey treatment course.

If that wasn't enough, Arrowhead Pharmaceuticals (NASDAQ:ARWR) andJohnson & Johnson (NYSE:JNJ) are also on their way to developing a treatment for hepatitis B. Clinical data for their candidate has looked solid. Whatever comes out of Vir's pipeline would have to compete with both existing standard-of-care treatments such as Entecavir and Tenofovir and new ones from other biotechs. This would significantly affect the company's pricing power in the event of its drug's approval.

Vir only brought in $67 million in combined licensing plus collaboration revenues in the past quarter. But currently, it has about $552.4 million in cash and investments, is operating at a net loss of $31.2 million per quarter, and has a $4.05 billion market cap. So in terms of its ability to keep moving forward with research and development, Vir's financial position is fair.

However, I don't think its shaky pipeline can justify its stock price, even after a recent decline. The market opportunities for hepatitis B and COVID-19 treatment candidates are too unstable and full of heavyweight pharma competitors. Buying Vir Biotechnology now could be like catching a falling knife. Investors looking at coronavirus stocks may wish to consider other opportunities.

Excerpt from:
Should You Buy Vir Biotechnology Stock on the Dip? - Motley Fool

A rating of 82 puts Fate Therapeutics Inc (FATE) near the top of the Biotechnology industry according to InvestorsObserver. Fate Therapeutics Inc's score of 82 means it scores higher than 82% of stocks in the industry. Fate Therapeutics Inc also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 29 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Fate Therapeutics Inc (FATE) stock has gained 2.6% while the S&P 500 has fallen -1.39% as of 1:41 PM on Friday, Sep 18. FATE is up $0.96 from the previous closing price of $36.91 on volume of 636,100 shares. Over the past year the S&P 500 is up 10.09% while FATE is up 112.04%. FATE lost -$1.57 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Fate Therapeutics Inc (FATE) Stock.

Read this article:
Is Fate Therapeutics Inc (FATE) a Winner in the Biotechnology Industry? - InvestorsObserver

This elaborate research report presented on Agricultural Biotechnology market is committed to present a deep-dive analysis of the product overview, sectioning details on decisive growth opportunities, development trends as well as growth deterrents, restricting growth at the world forum.

Our in-house research experts, subject matter experts and researchers have followed an extensive research analysis methodology, following stringent market research protocols such as the like of PESTEL and PORTERs Five Force analysis to arrive at logical deductions based on which market players and aspiring new entrants may witness seamless entry.

Leading Companies Reviewed in the Report are:

Syngenta AG, Monsanto, DuPont, Performance Plants Inc., Global Bio-Chem Technology Group, and ADAMA Agricultural Solutions are some of the key players in this industry

Get Exclusive Sample of Report on Agricultural Biotechnology market is available @ https://www.adroitmarketresearch.com/contacts/request-sample/113

Internal and external growth propellants inclusive of administrative initiatives, rigorous and aggressive investments made by various market participants, market players as well as aspiring new entrants seeking seamless integration in the global Agricultural Biotechnology market space are highly dominant alterations in global Agricultural Biotechnology market, opine our leading in-house R&D veterans and research analysts who invest in massive research activities.

This research report presentation gives complete access to highly discernable market specific developments in the realm of core development and growth facets, elaborating on vendor behavior as well as activity, complete with relevant information on market player investments and growth models that contribute towards a consistent growth trajectory in global Agricultural Biotechnology market.

Segment Assessment: Global Agricultural Biotechnology Market, 2020-25

This delicately orchestrated market representation, evaluating multiple factors and growth determinants are poised to assist high end growth directed business decisions in global Agricultural Biotechnology market.

The report. This decisive report presentation makes critical headways in defining the developments of the market comprising each of the segments and performance-based analysis across regions, besides also roping in significant details on country-specific performance.

Quick Read Table of Contents of this Report @ https://www.adroitmarketresearch.com/industry-reports/agricultural-biotechnology-market

DROT Review: Global Agricultural Biotechnology Market

Driver Analysis: This dedicated section of the report throws ample light on various favorable conditions and triggers prevalent in the market that induce optimum momentum

Threat & Barrier Diagnosis: This section of the report lends thoughts on distinctive evaluation and identification of market deterrents that stagnate high potential growth in the global Agricultural Biotechnology market

Opportunity Mapping: The section is highly incumbent in guiding market participants in diverting investments towards tapping new opportunities on both regional and global perspectives.

Report Investment a Logical Investment, Know Why?

* The report upholds a systematic presentation of all the tangible segments and their role in revenue optimization

* Further, the report also allows manufacturers and vendors to design appropriate investment discretion

* The report resonates critical findings on decisive factors such as downstream needs and requirement specifications as well as upstream product and service development

* The report aids in reader comprehension of the market based on dual parameters of value and volume.

* This report also helps market participants to organize R&D activities aligning with exact market requirements

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/113

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Follow this link:
Agricultural Biotechnology Market 2020 Growth Analysis, Opportunities Forecasts Report till 2025 By Top Companies- Syngenta AG, Monsanto, DuPont,...

The 63 rating InvestorsObserver gives to Ultragenyx Pharmaceutical Inc (RARE) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 76 percent of stocks in the Biotechnology industry, RAREs 63 overall rating means the stock scores better than 63 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Ultragenyx Pharmaceutical Inc (RARE) stock is trading at $80.17 as of 1:39 PM on Friday, Sep 18, a decline of -$2.25, or -2.73% from the previous closing price of $82.42. The stock has traded between $80.00 and $84.80 so far today. Volume today is below average. So far 199,806 shares have traded compared to average volume of 323,592 shares.

Click Here to get the full Stock Score Report on Ultragenyx Pharmaceutical Inc (RARE) Stock.

See the original post:
Is Ultragenyx Pharmaceutical Inc (RARE) the Top Pick in the Biotechnology Industry? - InvestorsObserver

A rating of 22 puts OncoCyte Corp (OCX) near the bottom of the Biotechnology industry according to InvestorsObserver. OncoCyte Corp's score of 22 means it scores higher than 22% of stocks in the industry. OncoCyte Corp also received an overall rating of 34, putting it above 34% of all stocks. Biotechnology is ranked 29 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 34 means the stock is more attractive than 34 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

OncoCyte Corp (OCX) stock is up 3.23% while the S&P 500 has fallen -0.51% as of 11:36 AM on Friday, Sep 18. OCX has gained $0.05 from the previous closing price of $1.55 on volume of 271,925 shares. Over the past year the S&P 500 is higher by 11.07% while OCX has fallen -27.27%. OCX lost -$0.51 per share the over the last 12 months.

Click Here to get the full Stock Score Report on OncoCyte Corp (OCX) Stock.

More:
Is OncoCyte Corp (OCX) the Top Pick in the Biotechnology Industry? - InvestorsObserver

The Biotechnology Crop Seeds Market share was valued at USD 50.82 billion in 2019 and it is projected to reach USD 86.59 billion by 2028 growing at a CAGR of 6.1% during the forecast period, 2016-2028. The market for Biotechnology Crop Seeds market has been segmented in major regions to understand the global development and demand patterns in this market. The Biotechnology Crop Seeds market has been segmented in North America, Eastern Europe, Western Europe, Asia Pacific, Middle East, & the Rest of the World.

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-68404?utm_source=Radhika/DC

With an emphasis on strategies, there have been several primary developments done by major companies such as Bayer, Corteva, KWS SAAT, Limagrain, China National Chemical

In terms of revenue and consumption of Biotechnology Crop Seeds, the Asia Pacific held a major market share globally in 2019. The Asia Pacific is expected to emerge as a relatively fast-growing region owing to the increasing demand from the paints & coating industry along with the growth in wood and plastic industries.

The market has been segmented as: By Product Type (Herbicide Tolerant, Insect Tolerant), By Application (Corn, Soybean)

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-68404?utm_source=Radhika/DC

This comprehensive market analysis explores market growth potential for Biotechnology Crop Seeds market that can help the stakeholders understand key developments and expectations in the market for Biotechnology Crop Seeds market-defining opportunities for growth and competitive scenarios. Moreover, the utilization of those products in industrial applications is beneficial for the reduction of cost and ensure fast cycle time.

Some of the key Impact Factors:

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-68404?utm_source=Radhika/DC

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: http://www.quincemarketinsights.com

See the rest here:
Biotechnology Crop Seeds Market Projected To Show Massive Growth By 2028 With Major Players Bayer, Corteva, KWS SAAT, Limagrain, China National...

A rating of 86 puts MannKind Corporation (MNKD) near the top of the Biotechnology industry according to InvestorsObserver. MannKind Corporation's score of 86 means it scores higher than 86% of stocks in the industry. MannKind Corporation also received an overall rating of 70, putting it above 70% of all stocks. Biotechnology is ranked 29 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 70 would rank higher than 70 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

MannKind Corporation (MNKD) stock has gained 2.85% while the S&P 500 has fallen -0.51% as of 11:45 AM on Friday, Sep 18. MNKD is up $0.06 from the previous closing price of $1.93 on volume of 1,755,208 shares. Over the past year the S&P 500 is higher by 11.07% while MNKD is up 50.76%. MNKD lost -$0.21 per share the over the last 12 months.

Click Here to get the full Stock Score Report on MannKind Corporation (MNKD) Stock.

Go here to see the original:
Is MannKind Corporation (MNKD) a Winner in the Biotechnology Industry? - InvestorsObserver

SEATTLE, Sept. 16, 2020 /PRNewswire/ -- AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients. This is AVM's second "safe to proceed" clinical trial authorization from the FDA within the past six months and demonstrates the broad potential of AVM's lead drug.

The previously approved study will evaluate AVM0703 in refractory/relapsed Non-Hodgkin's Lymphoma patients. This second study consists of two different ARDS patient populations: one with COVID-19-mediated moderate to severe ARDS and the other with Influenza-mediated severe ARDS.

AVM0703 is a novel and proprietary formulation of high concentration of dexamethasone. In addition to its recognized immunomodulatory properties, an acute high or suprapharmacologic dose of AVM0703 mobilizes highly active Natural Killer T- (NKT) and cytotoxic T- cells and dendritic cells. Within 6 hours of a single administration, there is evidence that AVM0703 "kick-starts" additional NKT cell activation. These cells have robust activity against very aggressive difficult-to-treat cancer models; this is directly relevant to COVID-19- and Influenza-mediated ARDS because NKT cells are programmed to eliminate abnormal cells, whether cancer or virus-infected.

Although generic formulations of dexamethasone are available, and daily low dosing has become a standard of care for moderately to severely ill COVID-19 patients, generic dexamethasone cannot be used at the high doses necessary to activate Natural Killer T (NKT), cytotoxic T and dendritic cells, and to stimulate monocyte ablation and reduce neutrophils. The excipients in these generic formulations exceed safe levels at the required doses needed to activate these immune cells. Importantly, one single dose of AVM0703 triggers this critical immune system activation.

While vaccines may play a part in thwarting COVID-19, it is entirely possible that COVID-19 infection will still occur in a significant number of people. Even with Influenza vaccines and antiviral drugs, a minimum of 17,000 Influenza patients develop ARDS in the USA each year. Therefore, therapies such as AVM0703 will most likely play a critical and continuing role in the future treatment of these patients.

"Quickly harnessing the body's own immune system to produce its own Natural Killer and cytotoxic T-cells and its own dendritic cells is appealing on many levels in treating seriously ill patients. Doing so has potentially broad applications in other diseases, including cancers." Janet R. Rea, AVM Biotechnology COO.

Rapid elimination of infected monocytes in COVID-19 patients could reduce ICU stays and decrease long-term lung damage. NKT mobilization could also provide long-term T-cell immunity. Due to its striking immunomodulatory properties, AVM0703 may have therapeutic effects in a variety of blood cancers, solid tumors, and infectious diseases such as COVID-19 and Influenza. Because NKT cells eliminate virus-infected cells independent of the strain or type of virus, this could provide immediately available therapy for future pandemics from any virus.

AVM Biotechnology is led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and three discoveries in clinical trials. Its COO, Janet R. Rea, has a proven track record working with federal regulators and successfully bringing drugs to market. The Executive Board is comprised of world leaders in the areas of respiratory illness, regulatory affairs, and vaccine development, and AVM is guided by a global Advisory Board including well-respected leaders in the areas of cancer and immunology. The company has received two SBIR grants, has filed for five worldwide Methods of Use patent families, has a worldwide Composition of Matter patent pending, and is committed to developing products that improve outcomes without additional suffering. They believe side effects from treatments should never be worse than the diseases themselves. This approval to begin an additional trial utilizing AVM0703 to treat ARDS patients is an exciting further step in support of that mission.

For more information, please contact Jena Dalpezjdalpez@avmbiotech.com

This contains certain statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and they may be accompanied by words such as "could," "would," "may," "potentially," "suggest," "believes," "expects," "should," and similar words or expressions. These forward-looking statements reflect our current views as of the date this is published, and are subject to risks, uncertainties, assumptions, changes in circumstances, and other factors; drug development and commercialization are highly risky and early clinical results in animals or humans may not reflect the full results from later stage or larger scale clinical trials. These forward-looking statements are subject to risks and uncertainties that could cause our actual results, performance, and expectations to differ materially from those expressed or implied by these statements, including statements about: future and ongoing drug development and timing; the applications of drugs to specific diseases; the potential for ongoing preclinical or clinical trial results; FDA or other regulatory findings and approvals; potential market opportunities; and the occurrence of future events or circumstances. There are risks and uncertainties involving and not limited to our ability to progress in our research and development efforts, complete clinical testing, achieve our expected results, commercialize our products, avoid infringement of patients, trademarks and other proprietary rights of third parties, protect products from competition, navigate the political environment, maintain sufficient capital and funding, avoid problems with our manufacturing processes, maintain our operations, and obtain regulatory approval to sell and market the drugs in the United States and elsewhere. The reader should not place any undue reliance on such forward-looking statements. We have no obligation to release publicly the results of any revisions to any of our forward-looking statements to reflect events or circumstances after the date these statements are made or to reflect the occurrence of unanticipated events, except as may be required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/seattle-avm-biotechnology-announces-second-ind-for-avm0703-clinical-trial-permitted-to-treat-covid-19-and-influenza-ards-with-its-supercharged-version-of-dexamethasone-301131932.html

SOURCE AVM Biotechnology, LLC

See original here:
Seattle AVM Biotechnology announces second IND for AVM0703: clinical trial permitted to treat COVID-19 and Influenza ARDS with its...

The 65 rating InvestorsObserver gives to Hepion Pharmaceuticals Inc (HEPA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 82 percent of stocks in the Biotechnology industry, HEPAs 65 overall rating means the stock scores better than 65 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Hepion Pharmaceuticals Inc (HEPA) stock has gained 7.06% while the S&P 500 is down -1.54% as of 11:45 AM on Thursday, Sep 17. HEPA has risen $0.24 from the previous closing price of $3.40 on volume of 759,104 shares. Over the past year the S&P 500 has risen 10.86% while HEPA has risen 20.53%. HEPA lost -$2.61 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Hepion Pharmaceuticals Inc (HEPA) Stock.

Read the original:
Is Hepion Pharmaceuticals Inc (HEPA) The Right Choice in Biotechnology? - InvestorsObserver

At the end of the latest market close, Vir Biotechnology Inc. (VIR) was valued at $32.96. In that particular session, Stock kicked-off at the price of $32.36 while reaching the peak value of $34.08 and lowest value recorded on the day was $31.29. The stock current value is $32.01.

Recently in News on September 9, 2020, Vir Biotechnology to Present at Cantor Global Virtual Healthcare Conference. Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., chief medical officer of Vir will present at the Cantor Global Virtual Healthcare Conference on Tuesday, September 15th at 8:20 am PT/ 11:20 am ET. You can read further details here

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology Inc. shares are logging -57.32% during the 52-week period from high price, and 174.75% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1815527 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology Inc. (VIR) recorded performance in the market was 154.55%, having the revenues showcasing -14.23% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.05B, as it employees total of 253 workers.

During the last month, 4 analysts gave the Vir Biotechnology Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 1 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 40.11, with a change in the price was noted -1.04. In a similar fashion, Vir Biotechnology Inc. posted a movement of -3.15% for the period of last 100 days, recording 1,363,658 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology Inc. in the period of last 50 days is set at 17.44%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 18.61%. In the last 20 days, the companys Stochastic %K was 18.00% and its Stochastic %D was recorded 15.66%.

Bearing in mind the latest performance of Vir Biotechnology Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 154.55%. The shares increased approximately by 13.19% in the 7-day charts and went up by -39.55% in the period of the last 30 days. Common stock shares were lifted by -14.23% during last recorded quarter.

Continued here:
Vir Biotechnology Inc. (VIR) market price of $32.01 offers the impression of an exciting value play - The InvestChronicle

OncoSec Medical Inc (ONCS) is around the top of the Biotechnology industry according to InvestorsObserver. ONCS received an overall rating of 68, which means that it scores higher than 68 percent of all stocks. OncoSec Medical Inc also achieved a score of 88 in the Biotechnology industry, putting it above 88 percent of Biotechnology stocks. Biotechnology is ranked 31 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

OncoSec Medical Inc (ONCS) stock is trading at $3.67 as of 1:07 PM on Monday, Sep 14, an increase of $0.40, or 12.23% from the previous closing price of $3.27. The stock has traded between $3.23 and $3.76 so far today. Volume today is 320,627 compared to average volume of 323,190.

Click Here to get the full Stock Score Report on OncoSec Medical Inc (ONCS) Stock.

Read more here:
Where Does OncoSec Medical Inc (ONCS) Stock Fall in the Biotechnology Field? - InvestorsObserver

SHANGHAI, Jan. 28, 2022 /PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed a US$40 million Series A financing to advance the preclinical and clinical development of its series of innovative antibodies and other biologics products. This round of financing was jointly led by OrbiMed and Hankang Capital, followed by Yonghua Investment and Elikon Investment. Before the completion of this round of financing, HanBio was an early product research and development company incubated by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian"). The company's current pipeline includes three bispecific antibodies in the IND and pre-IND stages, and a variety of early-stage antibodies and other biologics products.

Dr. Zhenping Zhu, Founder, Chairman and Chief Executive Officer of HanBio, said, "We highly appreciate OrbiMed and Hankang Capital and the other investors for their recognition of HanBio's R&D capability, its innovative pipeline and overall development strategy. This round of funds will be used for preclinical research and clinical trials of our multiple antibody and bispecific antibody products, as well as the establishment of an efficient company management and R&D team. We expect to submit IND applications to the regulatory agencies in both China and the United States for three innovative bispecific antibody products in 2022. On the research front we will focus on exploring new therapeutic targets and modalities, and developing innovative medicines with better safety and efficacy profiles to the current standard treatment options."

Dr. Zhu has extensive experience and an excellent track record in the biopharmaceutical industrial field, including more than 28 years of research and management experience in several world-renowned pharmaceutical companies. Prior to founding HanBio, Dr. Zhu served as the President of R&D and Chief Scientific Officer of 3SBio Group. Before joining 3SBio, Dr. Zhu has served as Executive Vice President at Kadmon Holdings, Vice President and Global Head of Protein Sciences at Novartis Biologics, and Vice President of Research at ImClone Systems. Dr. Zhu has contributed greatly to the discovery and development of a number of therapeutic antibody products approved by the US FDA, European EMA and China NMPA; he is the patent inventor of both ramucirumab (CyramzaR) and necitumumab (PortrazzaR), and one of the main contributors to cetuximab (ErbituxR). Dr. Zhu has published more than 200 peer-reviewed scientific papers in international journals, and has applied for or obtained more than 150 patents in China, United States and other international territories.

Dr. Jing Lou, Chairman of Sunshine Guojian, said, "I am very glad that HanBio, as an early product R&D company incubated by Sunshine Guojian, is recognized by leading biotech investors. Sunshine Guojian is committed to working with the investors to fully support HanBio for the rapid development of the company's innovative products that will benefit cancer patients in China and around the world."

Dr. Steven Dasong Wang, Partner at OrbiMed, said, "Dr. Zhu is one of the pioneers and leaders in the global biopharmaceutical industry. Several antibody products he invented or greatly contributed to, including ramucirumab (CyramzaR) and cetuximab (ErbituxR), have become ones of the most prescribed biologics in the treatment of gastric and colorectal cancers, with total global annual sales nearing 3 billion US dollars. HanBio led by Dr. Zhu has impressed us with its holistic approach to target selection, antibody discovery and design, and clinical translation strategy with special focus on cancers of the human digestive system. We look forward to supporting the company in advancing product clinical development and achieving breakthroughs in the treatment of cancers with high prevalence in China."

Mr. Quanhong Yuan, Partner at Hankang Capital, said, "PD1/PDL1 antibodies have reshaped the landscape of cancer treatment, but they also face the problem of limited response rate. Combination therapies and bispecific antibodies represent a new wave of therapeutic modalities, and are expected to provide a breakthrough solution to the treatment of PD1/PD1 resistant tumors. Dr. Zhu and his team at HanBio have rich experience and excellent track record in the field of antibody drug R&D and tumor immunotherapy. We expect HanBio to achieve great success in the field of cancer treatment."

About HanBio Therapeutics

"Transformative Medicines by Innovation."HanBio Therapeutics is an innovative biotechnology company committed to researching and developing next generation transformative medicines to treat patients with serious diseases.

For more information, please contact:Zhenping Zhu, MD, PhDEmail:[emailprotected][emailprotected]

Tel:+1 347 327 0705 (USA) +011 86 186 1234 0399 (China)

SOURCE HanBio Therapeutics

Continue reading here:
HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital - PRNewswire

WASHINGTON--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO) today announced a new, strategic direction that will help guide it to achieving long-term goals while maintaining responsiveness to changing political headwinds.

Announcing the new vision, mission and purpose to member companies, BIOs recently appointed President and CEO, Dr. Michelle McMurry-Heath remarked, We need to be the face and the voice of sciencespeaking up for the millions of families around the globe who depend upon our success. That means being bold, memorable, andat timesprovocative. But if we are as proud of our scientists and as committed to our patients and consumers as I know we are, then it is not only the best tactic, it is our duty.

After at least 106 one-on-one conversations with member companies, extensive strategic planning sessions, a broad membership survey and several focus groups, BIO outlined the new direction through

BIO plans to execute on the strategic direction though five different pillars:

The Board and staff of the nearly 1000-member organization plan to operationalize the five pillars beginning immediately. For more information on BIOs new strategic direction, visit http://www.bio.org/strategic-vision.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

See the article here:
New Strategic Vision for Biotechnology Innovation Organization - Business Wire

The 62 rating InvestorsObserver gives to Dare Bioscience Inc (DARE) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, DAREs 62 overall rating means the stock scores better than 62 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Dare Bioscience Inc (DARE) stock is trading at $2.34 as of 1:25 PM on Tuesday, Jan 19, a gain of $0.90, or 62.5% from the previous closing price of $1.44. The stock has traded between $1.41 and $2.68 so far today. Volume today is high. So far 26,044,216 shares have traded compared to average volume of 1,477,335 shares.

Click Here to get the full Stock Score Report on Dare Bioscience Inc (DARE) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Visit link:
Is Dare Bioscience Inc (DARE) The Right Choice in Biotechnology? - InvestorsObserver

Myovant Sciences Ltd (MYOV) is around the top of the Biotechnology industry according to InvestorsObserver. MYOV received an overall rating of 77, which means that it scores higher than 77 percent of all stocks. Myovant Sciences Ltd also achieved a score of 93 in the Biotechnology industry, putting it above 93 percent of Biotechnology stocks. Biotechnology is ranked 30 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Myovant Sciences Ltd (MYOV) stock is trading at $25.07 as of 10:49 AM on Monday, Jan 4, a drop of -$2.55, or -9.23% from the previous closing price of $27.62. The stock has traded between $25.04 and $27.70 so far today. Volume today is light. So far 551,426 shares have traded compared to average volume of 1,166,838 shares.

Click Here to get the full Stock Score Report on Myovant Sciences Ltd (MYOV) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original post:
Is Myovant Sciences Ltd (MYOV) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Allonnia is a new company dedicated to finding and using synthetic biological solutions to waste. Just this month, the venture spun out from the Ginkgo Bioworks Ferment Consortium.

The Corsotium exists as part of the biotech companys business in order to find way to partner and innovate in the biological engineering space and to develop new companies that can effect change in existing markets.

We started the Ferment Consortium because we believe that with the right partners and funding, biology can progress solutions to urgent challenges, says Jason Kelly, CEO and Co-Founder of Ginkgo Bioworks, in a recent media release about the new company.

Investing in Allonnia, he says,is a perfect fit for that mission, and we're incredibly fortunate to have Nicole [Richards] at the company's helm. Her knowledge and credibility will be invaluable in helping Allonnia quickly bring innovative environmental solutions to market.

Explaining the premise behind the new company further, Kelly say,As one of biology's fundamental roles in nature is to break things down, there is a huge diversity of microbes and enzymes that can clean up waste. This application of biology represents both an enormous market and a worldwide environmental challenge.

Waste pollution is quickly becoming one of the most pivotal environmental issues impacting both public and planetary health, and I'm thrilled to be joining a company focused on solving these critical challenges in new ways, says Nicole Richards, who serves as Allonnias first CEO.

Our ultimate goal, she says in the recent media release,is to accelerate the R&D process for biological treatment solutions across the board, picking up where chemical and mechanical solutions have reached their maximum impact. With the support, expertise and backing from Ginkgo and our investors, I feel confident that Allonnia can drive transformational change within the water and waste management industries.

The company has secured $40m in Series A funding to get started in the waste treatment space. And among Allonnias early initiatives will be one to develop a biotech degradation solution to so-called forever chemicals like PFAS, PFOA, and PFOS.

Existing processes for treating forever chemicals require high energy consumption and chemical use, and still only sequester or landfill the contaminant rather than removing it from the environment entirely, explains the release.

And with advancing biotech, the right funding and support, and the knowledge of experts and professionals like Richards, Allonnia expects to change that. Richards most previously worked as Growth, Strategy and M&A Director for Water Solutions at DuPont. Before that, she spent more than a decade with Solvay.

View post:
Can biotechnology make PFAS and other so-called forever chemicals degradable? - CosmeticsDesign.com USA

Today well do a simple run through of a valuation method used to estimate the attractiveness of B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) as an investment opportunity by estimating the companys future cash flows and discounting them to their present value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Models like these may appear beyond the comprehension of a lay person, but theyre fairly easy to follow.

Remember though, that there are many ways to estimate a companys value, and a DCF is just one method. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

See our latest analysis for B.R.A.I.N. Biotechnology Research and Information Network

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second steady growth period. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these arent available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

(Est = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = 12m

The second stage is also known as Terminal Value, this is the businesss cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 0.2%. We discount the terminal cash flows to todays value at a cost of equity of 5.7%.

Terminal Value (TV)= FCF2030 (1 + g) (r g) = 11m (1 + 0.2%) (5.7% 0.2%) = 192m

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= 192m ( 1 + 5.7%)10= 110m

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is 122m. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of 7.4, the company appears slightly overvalued at the time of writing. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. You dont have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a companys future capital requirements, so it does not give a full picture of a companys potential performance. Given that we are looking at B.R.A.I.N. Biotechnology Research and Information Network as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation weve used 5.7%, which is based on a levered beta of 0.919. Beta is a measure of a stocks volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Whilst important, the DCF calculation ideally wont be the sole piece of analysis you scrutinize for a company. DCF models are not the be-all and end-all of investment valuation. Preferably youd apply different cases and assumptions and see how they would impact the companys valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Why is the intrinsic value lower than the current share price? For B.R.A.I.N. Biotechnology Research and Information Network, weve put together three essential aspects you should further examine:

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the XTRA every day. If you want to find the calculation for other stocks just search here.

PromotedIf youre looking to trade B.R.A.I.N. Biotechnology Research and Information Network, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

Continue reading here:
B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Shares Could Be 20% Above Their Intrinsic Value Estimate - Simply Wall St

Plant Biotechnology Services Market Report Delivering Growth Analysis with Key Trends of Top Companies (2020-2026)

A comprehensive research study on the Plant Biotechnology Services Marketwas recently published by Market Report Expert. This is an up-to-date report, covering the current COVID-19 impact on the market. The Coronavirus (COVID-19) has affected every aspect of life globally and thus altering the global market scenario. The changes in the market conditions are drastic. The swiftly changing market scenario and initial and future assessment of the impact on Plant Biotechnology Services market is covered in the report.The Plant Biotechnology Services Market report is a precise and deep-dive study on the current state that aims at the major drivers, market strategies, and imposing growth of the key players. Worldwide Plant Biotechnology Services Industry also offers a granular study of the dynamics, segmentation, revenue, share forecasts, and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Plant Biotechnology Services industry.

The Global Plant Biotechnology Services Market poised to grow from US$ XX million in 2020 to US$ XX million by 2026 at a compound annual growth rate (CAGR) of XX% during the projection period of 2020-2026.

An Outline of the Major Key Players covered in this Report:

Thermo Fisher Scientific Inc., Agilent Technologies, GenScript Biotech Corporation, Eurofins Scientific SE

Get Free LatestPDF Template of this Report(Including Covid-19 impact analysis on overall industry Forecast, Size, Share, CAGR and more.)@ https://www.marketreportexpert.com/report/Plant_Biotechnology_Services/13966/sample

Note: We can also provide market report in German/French Language.

The report puts together a succinct analysis of the growth drivers influencing the current business scenario across various regions and countries. Substantial information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present a collaborative prediction. Additionally, this report encompasses a precise competitive analysis of major market players, innovative companies, and their strategies during the projection timeline.

The latest report on the Plant Biotechnology Services Market consists of an analysis of this industry and its type, application, and other segments. As per the report, the market is estimated to gain significant returns and register substantial y-o-y growth during the forecast period of 2020-2026.

Majortype, primarily split into

Genomics ServicesAnalytical ChemistryCellular ImagingForage AnalysisTransformation Services

Major applications/end users, including

Research InstitutesPharmaceuticals CompaniesBiotechnology Companies

According to the report, the study offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections. The report documents factors such as drivers, restraints, and opportunities that impacts the remuneration of this market.

Feel Free! Ask Our Industry Expert For Discount on this Report(Note: Our reports include the analysis of the impact of COVID-19 on this industry. Our updated sample pages shows impact of Covid-19 on Industry trends. Also we are offering 20% discount.): https://www.marketreportexpert.com/report/Plant_Biotechnology_Services/13966/inquiry

The research offers an analysis of the geographical landscape of the Plant Biotechnology Services Market, which is divided into regions such as North America, Europe, Asia Pacific, South America, and the Middle East & Africa. The segment includes data about several parameters related to the regional contribution such as market share, application share, type share, key companies in respective regions, market share of key companies in regional market, growth rate and revenue of the regional market, sales, production, and consumption of the respective Plant Biotechnology Services market.

Major Highlights of TOC Covers:

Plant Biotechnology Services Market 2020, Plant Biotechnology Services Market size, Plant Biotechnology Services Market share, Plant Biotechnology Services Market analysis, Plant Biotechnology Services Market forecast, Plant Biotechnology Services Market trends, Plant Biotechnology Services Market Research report, Plant Biotechnology Services application, Plant Biotechnology Services Trends, Plant Biotechnology Services Market growing CAGR, Plant Biotechnology Services Market Competitive Landscape, Plant Biotechnology Services Market Growth

Information related to the growth rate, revenue, sales, production, consumption, during the forecast period is included in the report. The Plant Biotechnology Services Market report claims that the industry is projected to generate significant revenue and sales during the forecast period. The report consists of information related to the market dynamics such as challenges involved in this vertical, growth opportunities, and driving factors affecting the market.

About Us

Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.

Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email inquiry@marketreportexpert.comWeb:-https://www.marketreportexpert.com

Read more from the original source:
Plant Biotechnology Services Market Increasing Demand with Leading Player, Comprehensive Analysis 2026| Thermo Fisher Scientific Inc., Agilent...